Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Paper
  • Published:

Growth inhibition and modulation of kinase pathways of small cell lung cancer cell lines by the novel tyrosine kinase inhibitor STI 571

Oncogene volume 19, pages 3521–3528 (2000)Cite this article

Abstract

Small cell lung cancer (SCLC) is an aggressive cancer characterized by several autocrine growth mechanisms including stem cell factor and its receptor c-Kit. In order to arrive at potentially new and novel therapy for SCLC, we have investigated the effects of the tyrosine kinase inhibitor, STI 571, on SCLC cell lines. It has been previously reported that STI 571 does not only inhibit cellular Abl tyrosine kinase activity but also the PDGF receptor and c-Kit tyrosine kinases at similar concentrations (approximately 0.1 μM). There is no expression of the PDGF-receptor, and the Abl kinase is not activated by SCLC, but over 70% of SCLC contain the c-Kit receptor. Utilizing this preliminary data, we have determined that three (NCI-H69, NCI-H146 and NCI-H209) of five (including NCI-H82 and NCI-H249) SCLC cell lines had detectable c-Kit receptors and were inhibited in growth and viability at concentrations 1–5 μM of STI 571 after 48 h of treatment. The SCLC cell lines, NCI-H69, NCI-H146 and NCI-H209, showed a dose-response (tested between 0.1–10 μM) inhibition of tyrosine phosphorylation of c-Kit as well as in vitro kinase activity (at 5 μM) of c-Kit in response to STI 571. STI 571 inhibited cell motility, as assessed by time-lapsed video microscopy, within 6 h of STI 571 treatment (5 μM). STI 571 also decreased intracellular levels of reactive oxygen species (ROS) by at least 60%, at a concentration (5 μM) that also inhibited cell growth. Cell cycle analysis of STI 571 responsive cells showed that cells were generally slowed in G2/M phase, but there was no arrest at G1/S. A downstream phosphorylation target of c-Kit, Akt, was not phosphorylated in response to stem cell factor in the presence of STI 571. These data imply that STI 571 inhibits growth of SCLC cells through a mechanism that involves inactivation of the tyrosine kinase c-Kit. The effectiveness of STI 571 in this study suggests this drug may be useful in a clinical trial, for patients with SCLC.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6
Figure 7

Similar content being viewed by others

References

  • Buchdunger E, Zimmermann J, Mett H, Meyer T, Muller M, Druker BJ and Lydon NB. . 1996 Cancer Res. 56: 100–104.

  • Carroll M, Ohno-Jones S, Tamura S, Buchdunger E, Zimmermann J, Lydon NB, Gilliland DG and Druker BJ. . 1997 Blood 90: 4947–4952.

  • Chaudhry A, Carrasquillo JA, Avis IL, Shuke N, Reynolds JC, Bartholomew R, Larson SM, Cuttitta F, Johnson BE and Mulshine JL. . 1999 Clin. Cancer Res. 5: 3385–3393.

  • Chute JP, Chen T, Feigal E, Simon R and Johnson BE. . 1999 J. Clin. Oncol. 17: 1794–1801.

  • DiPaola RS, Kuczynski WI, Onodera K, Ratajczak MZ, Hijiya N, Moore J and Gewirtz AM. . 1997 Cancer Gene Ther. 4: 176–182.

  • Druker BJ and Lydon NB. . 2000 J. Clin. Invest. 105: 3–7.

  • Druker BJ, Talpaz M, Resta D, Peng B, Buchdunger E, Ford J and Sawyers C. . 1999 Blood 94: 368a.

  • Druker BJ, Tamura S, Buchdunger E, Ohno S, Segal GM, Fanning S, Zimmermann J and Lydon NB. . 1996 Nat. Med. 2: 561–566.

  • Ferry D, Hammond L, Ranson M, Kris M, Miller V, Murray P, Tullo A, Feyereislova A, Averbuch S and Rowinsky E. . 2000 Proc. ASCO. 19: 3a.

  • Hibi K, Takahashi T, Sekido Y, Ueda R, Hida T, Ariyoshi Y and Takagi H. . 1991 Oncogene 6: 2291–2296.

  • Johnson BE and Kelley MJ. . 1995 Lung Cancer 12: S5–S16.

  • Krystal GW, Hines SJ and Organ CP. . 1996 Cancer Res. 56: 370–376.

  • Plummer HD, Catlett J, Leftwich J, Armstrong B, Carlson P, Huff T and Krystal G. . 1993 Cancer Res. 53: 4337–4342.

  • Salgia R, Li JL, Ewaniuk DS, Pear W, Pisick E, Burky SA, Ernst T, Sattler M, Chen LB and Griffin JD. . 1997 J. Clin. Invest. 100: 46–57.

  • Salgia R, Li JL, Ewaniuk DS, Wang YB, Sattler M, Chen WC, Richards W, Pisick E, Shapiro GI, Rollins BJ, Chen LB, Griffin JD and Sugarbaker DJ. . 1999a Oncogene 18: 67–77.

  • Salgia R, Li JL, Lo SH, Brunkhorst B, Kansas GS, Sobhany ES, Sun Y, Pisick E, Hallek M, Ernst T, Tantravahi R, Chen LB and Griffin JD. . 1995 J. Biol. Chem. 270: 5039–5047.

  • Salgia R, Lin J, Narsimhan R, Chen W, Mach N, Dranoff G, Sattler M and Griffin J. . 1998 Blood 92: 487a.

  • Salgia R, Quackenbush E, Lin J, Souchkova N, Sattler M, Ewaniuk DS, Klucher KM, Daley GQ, Kraeft SK, Sackstein R, Alyea EP, von Andrian UH, Chen LB, Gutierrez-Ramos JC, Pendergast AM and Griffin JD. . 1999b Blood 94: 4233–4246.

  • Sattler M and Salgia R. . 1997 Cytokine Growth Factor Rev. 8: 63–79.

  • Sattler M, Salgia R, Shrikhande G, Verma S, Pisick E, Prasad KV and Griffin JD. . 1997 J. Biol. Chem. 272: 10248–10253.

  • Sattler M, Verma S, Byrne CH, Shrikhande G, Winkler T, Algate PA, Rohrschneider LR and Griffin JD. . 1999a Mol. Cell. Biol. 19: 7473–7480.

  • Sattler M, Winkler T, Verma S, Byrne CH, Shrikhande G, Salgia R and Griffin JD. . 1999b Blood 93: 2928–2935.

  • Sawyers CL and Druker B. . 1999 Cancer. J. Sci. Am. 5: 63–69.

Download references

Acknowledgements

This work was supported by NIH grant CA75348-03 and Lowe's Center for Thoracic Oncology (R. Salgia), and Leukemia Research Foundation Fellowship (M. Sattler).

Author information

Authors and Affiliations

  1. Department of Adult Oncology, and Departments of Medicine, Dana-Farber Cancer Institute, Brigham and Women's Hospital, and Harvard Medical School, Boston, 02115, Massachusetts, MA, USA

    Wen-Lan Wang, Mary Ellen Healy, Martin Sattler, Shalini Verma, Jeffrey Lin, Gautam Maulik, James D Griffin, Bruce E Johnson & Ravi Salgia

  2. Department of Cancer Biology, and Departments of Medicine, Dana-Farber Cancer Institute, Brigham and Women's Hospital, and Harvard Medical School, Boston, 02115, Massachusetts, MA, USA

    Charles D Stiles

Authors
  1. Wen-Lan Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mary Ellen Healy
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Martin Sattler
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Shalini Verma
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Jeffrey Lin
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Gautam Maulik
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Charles D Stiles
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. James D Griffin
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Bruce E Johnson
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Ravi Salgia
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Wang, WL., Healy, M., Sattler, M. et al. Growth inhibition and modulation of kinase pathways of small cell lung cancer cell lines by the novel tyrosine kinase inhibitor STI 571. Oncogene 19, 3521–3528 (2000). https://doi.org/10.1038/sj.onc.1203698

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1203698

Keywords

This article is cited by

Search

Advanced search

Quick links